Neuren Pharmaceuticals Limited

As of December 31, 2025, Neuren Pharmaceuticals Limited carries a market capitalization of 2.36B, placing it among publicly traded companies globally. Its enterprise value stands at 2.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neuren Pharmaceuticals Limited's next confirmed earnings release is scheduled for February 24, 2027.

As of December 31, 2025, Neuren Pharmaceuticals Limited has 126.64M shares outstanding.

As of December 31, 2025, Neuren Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 78.41. The price-to-sales ratio is 36.92, and the price-to-book ratio stands at 6.96.

As of December 31, 2025, Neuren Pharmaceuticals Limited trades at an EV/EBITDA multiple of 93.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 31.88 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 93.66 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.06B versus a market cap of 2.36B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Neuren Pharmaceuticals Limited maintains a current ratio of 76.60, meaning it holds 76.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2025, Neuren Pharmaceuticals Limited posted a return on equity (ROE) of 8.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.62 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.67, useful for judging operating efficiency across full business cycles.

Over the twelve months ended December 31, 2025, Neuren Pharmaceuticals Limited recorded 8.49M in income tax expense. That works out to an effective tax rate of 21.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 38.93M, leaving 30.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Neuren Pharmaceuticals Limited's stock has declined approximately 7.39% over the past 52 weeks. The 50-day moving average sits at 20.65, while the 200-day moving average is 16.08.

Over the twelve months ended December 31, 2025, Neuren Pharmaceuticals Limited generated 64.63M in revenue and converted that into 30.44M in net income, yielding earnings per share of 0.23. EBITDA reached 22.02M, while operating income came in at 22.00M.

These figures are as of December 31, 2025. Total book value stands at 338.45M, with working capital of 327.90M providing operational flexibility.

These figures cover the twelve months ended December 31, 2025.

These figures cover the twelve months ended December 31, 2025. The operating margin of 34.04 and net profit margin of 47.09 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Total shareholder yield reaches 1.41, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Neuren Pharmaceuticals Limited shareholders.

Neuren Pharmaceuticals Limited's most recent stock split took place on November 30, 2017 with a 20:1 split ratio.

As of December 31, 2025, Neuren Pharmaceuticals Limited has an Altman Z-Score of 323.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.